UTI Universal Technical Institute (UTI) Insider Trading, Ownership & Congress Trades
Services · Services-educational services · CIK 0001261654
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
159
13F, latest reported quarter
What the filings say about UTI
Insiders, 180 days
-$128.7M net sold
1 buyer · 5 sellers · 0% of sales under a 10b5-1 plan
Universal Technical Institute insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, UNIVERSAL TECHNICAL INSTITUTE INC insiders sold a net $128.7M of stock across 77 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 9 earlier Form 4 trades (code P or S) here by this insider (7 buys, 2 sales), the last on Sep 21, 2026.
- The trade is 0.7% of the 153,330 shares held after it.
- No other insider bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEVINCENZI ROBERT THOMAS bought about $19.7K of UTI on Sep 28, 2026; 159 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (6 buys, 2 sales), the last on Aug 27, 2026.
- The trade is 0.7% of the 152,330 shares held after it.
- No other insider bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEVINCENZI ROBERT THOMAS bought about $19.8K of UTI on Sep 21, 2026; 159 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (5 buys, 2 sales), the last on Aug 25, 2026.
- The trade is 0.7% of the 151,330 shares held after it.
- No other insider bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEVINCENZI ROBERT THOMAS bought about $21.8K of UTI on Aug 27, 2026; 159 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (4 buys, 2 sales), the last on Aug 12, 2026.
- The trade is 0.7% of the 150,330 shares held after it.
- No other insider bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEVINCENZI ROBERT THOMAS bought about $21.8K of UTI on Aug 25, 2026; 159 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (3 buys, 2 sales), the last on Aug 10, 2026.
- The trade is 0.7% of the 149,330 shares held after it.
- No other insider bought within 30 days.
- 159 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEVINCENZI ROBERT THOMAS bought about $25.9K of UTI on Aug 12, 2026; 159 funds added in the latest 13F quarter.77 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$128.7M over 180 days
+$334.7K over 90 days
below 97% of Services
Congress
no House purchase disclosed in the last 12 months
Funds
159 funds bought in last quarter
more than 65% of Services
Revenue
+14.0% year over year
more than 68% of Services
Margin
7.5% net margin
more than 68% of Services
Buybacks
no share repurchases reported
Short interest
12.9% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
more than 91% of Services
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Sep 30Director DEVINCENZI ROBERT THOMAS bought $19.7K (Sep 28)
Watch UTI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.0%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns UTI: institutional holders (13F)
13F holdings, latest reported quarter
7,553,895 sh
$323.1M
3,000,595 sh
$128.3M
2,499,689 sh
$106.9M
2,211,159 sh
$94.6M
1,890,902 sh
$80.9M
Congress trades in UTI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
UTI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Grant Jerome Alan
Filed 2026-06-29
$3.9M
Prehn Kevin
Filed 2026-06-22
$181.8K
UTI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Rockefeller US Small Cap Core Fund
$2.7M position · as of 2026-05-31
2.7%
RiverPark/Next Century Growth Fund
$270.2K position · as of 2026-06-30
2.2%
Congress Small Cap Growth Fund
$39.3M position · as of 2026-07-31
2.0%
Needham Aggressive Growth Fund
$48.3M position · as of 2026-06-30
1.9%
Wasatch Micro Cap Fund
$12.0M position · as of 2026-06-30
1.8%
CONESTOGA SMALL CAP FUND
$33.5M position · as of 2026-06-30
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Troy R. Anderson
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$3.0M
$3.9M
$1.2M
+65%
+15%
2022
$1.9M
$2.0M
$923.8K
+7%
-10%
2021
$2.2M
$2.2M
$872.0K
+33%
+2%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $128.7M sold by insiders over 180 days, 159 funds added last quarter. Each figure is a federal filing, dated the day it went public.
UTI financials
Revenue growth
+14.0%
XBRL, annual
Net margin
7.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$883.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM UTI
| FY Sep 2025 | $835.6M |
| FY Sep 2024 | $732.7M |
| FY Sep 2023 | $607.4M |
| FY Sep 2022 | $418.8M |
| FY Sep 2021 | $335.1M |
| Jun 2026 | $218.9M |
| Mar 2026 | $221.4M |
| Dec 2025 | $220.8M |
| Sep 2025 | $222.4M |
| Jun 2025 | $204.3M |
| Mar 2025 | $207.4M |
| Dec 2024 | $201.4M |
| Sep 2024 | $196.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+3.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM UTI
| FY Sep 2025 | +7.5% |
| FY Sep 2024 | +5.7% |
| FY Sep 2023 | +2.0% |
| FY Sep 2022 | +6.2% |
| FY Sep 2021 | +4.4% |
| Jun 2026 | +1.0% |
| Mar 2026 | +0.2% |
| Dec 2025 | +5.8% |
| Sep 2025 | +8.4% |
| Jun 2025 | +5.2% |
| Mar 2025 | +5.5% |
| Dec 2024 | +11.0% |
| Sep 2024 | +9.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$22.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM UTI
| FY Sep 2025 | $55.4M |
| FY Sep 2024 | $61.6M |
| FY Sep 2023 | -$7.5M |
| FY Sep 2022 | -$33.4M |
| FY Sep 2021 | -$6.1M |
| Jun 2026 | -$17.9M |
| Mar 2026 | -$26.4M |
| Dec 2025 | -$19.2M |
| Sep 2025 | $40.6M |
| Jun 2025 | $6.8M |
| Mar 2025 | -$11.7M |
| Dec 2024 | $19.6M |
| Sep 2024 | $60.0M |
At each fiscal year end
Single quarter
Debt to equity
0.46x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity UTI
| FY Sep 2025 | 0.27x |
| FY Sep 2024 | 0.48x |
| FY Sep 2023 | 0.72x |
| FY Sep 2022 | 0.31x |
| FY Sep 2021 | 0.16x |
| Jun 2026 | 0.46x |
| Mar 2026 | 0.38x |
| Dec 2025 | 0.30x |
| Sep 2025 | 0.27x |
| Jun 2025 | 0.24x |
| Mar 2025 | 0.32x |
| Dec 2024 | 0.43x |
| Sep 2024 | 0.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.47x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt UTI
| FY Sep 2025 | 1.12x |
| FY Sep 2024 | 0.68x |
| FY Sep 2023 | 0.30x |
| FY Sep 2022 | 0.68x |
| FY Sep 2021 | 1.80x |
| Jun 2026 | 0.47x |
| Mar 2026 | 0.63x |
| Dec 2025 | 0.76x |
| Sep 2025 | 1.12x |
| Jun 2025 | 1.46x |
| Mar 2025 | 1.06x |
| Dec 2024 | 0.82x |
| Sep 2024 | 0.68x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+10.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity UTI
| FY Sep 2025 | +21.4% |
| FY Sep 2024 | +17.3% |
| FY Sep 2023 | +5.6% |
| FY Sep 2022 | +12.8% |
| FY Sep 2021 | +8.0% |
| Jun 2026 | +10.5% |
| Mar 2026 | +13.5% |
| Dec 2025 | +17.4% |
| Sep 2025 | +21.4% |
| Jun 2025 | +23.1% |
| Mar 2025 | +21.8% |
| Dec 2024 | +21.4% |
| Sep 2024 | +17.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets UTI
| FY Sep 2025 | +8.0% |
| FY Sep 2024 | +5.7% |
| FY Sep 2023 | +1.9% |
| FY Sep 2022 | +4.9% |
| FY Sep 2021 | +3.1% |
| Jun 2026 | +4.2% |
| Mar 2026 | +5.4% |
| Dec 2025 | +6.8% |
| Sep 2025 | +8.0% |
| Jun 2025 | +8.7% |
| Mar 2025 | +8.1% |
| Dec 2024 | +7.2% |
| Sep 2024 | +5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+8.7%
operating income after a 24.2% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital UTI
| FY Sep 2025 | +26.4% |
| FY Sep 2024 | +20.7% |
| FY Sep 2023 | +5.3% |
| FY Sep 2022 | n/a |
| FY Sep 2021 | +13.3% |
| Jun 2026 | +8.7% |
| Mar 2026 | +11.7% |
| Dec 2025 | +19.1% |
| Sep 2025 | +26.4% |
| Jun 2025 | +25.0% |
| Mar 2025 | +23.2% |
| Dec 2024 | +25.9% |
| Sep 2024 | +20.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed UTI
| FY Sep 2025 | +14.7% |
| FY Sep 2024 | +10.8% |
| FY Sep 2023 | +4.4% |
| FY Sep 2022 | +5.6% |
| FY Sep 2021 | +4.3% |
| Jun 2026 | +7.1% |
| Mar 2026 | +9.4% |
| Dec 2025 | +12.3% |
| Sep 2025 | +14.7% |
| Jun 2025 | +15.5% |
| Mar 2025 | +14.5% |
| Dec 2024 | +13.1% |
| Sep 2024 | +10.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
36.05x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing UTI
| FY Sep 2025 | 28.81x |
| FY Sep 2024 | 21.39x |
| FY Sep 2023 | 76.18x |
| FY Sep 2022 | 14.32x |
| FY Sep 2021 | 48.29x |
| Jun 2026 | 70.11x |
| Mar 2026 | 47.50x |
| Dec 2025 | 27.22x |
| Sep 2025 | 28.81x |
| Jun 2025 | 29.22x |
| Mar 2025 | 24.23x |
| Dec 2024 | 25.97x |
| Sep 2024 | 21.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.2B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value UTI
| FY Sep 2025 | $1.7B |
| FY Sep 2024 | $838.8M |
| FY Sep 2023 | $296.1M |
| FY Sep 2022 | $184.8M |
| FY Sep 2021 | $118.9M |
| Jun 2026 | $2.4B |
| Mar 2026 | $2.0B |
| Dec 2025 | $1.4B |
| Sep 2025 | $1.7B |
| Jun 2025 | $1.8B |
| Mar 2025 | $1.4B |
| Dec 2024 | $1.3B |
| Sep 2024 | $838.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield UTI
| FY Sep 2025 | +3.1% |
| FY Sep 2024 | +7.0% |
| FY Sep 2023 | -2.6% |
| FY Sep 2022 | -18.2% |
| FY Sep 2021 | -2.8% |
| Jun 2026 | -1.0% |
| Mar 2026 | +0.1% |
| Dec 2025 | +1.2% |
| Sep 2025 | +3.1% |
| Jun 2025 | +4.1% |
| Mar 2025 | +5.1% |
| Dec 2024 | +5.3% |
| Sep 2024 | +7.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -47%, PEG needs growth
PEG, trailing UTI
| FY Sep 2025 | 0.59x |
| FY Sep 2024 | 0.04x |
| FY Sep 2023 | n/a |
| FY Sep 2022 | 0.08x |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.59x |
| Jun 2025 | 0.22x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.09x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $835.6M | $732.7M | $607.4M | $418.8M |
| Operating income | $83.5M | $58.9M | $21.4M | $22.4M |
| Net income | $63.0M | $42.0M | $12.3M | $25.8M |
| EPS (diluted) | 1.13 | 0.75 | 0.13 | 0.38 |
| Operating cash flow | $97.3M | $85.9M | $49.1M | $46.0M |
| Cash | $127.4M | $161.9M | $151.5M | $66.5M |
| Long-term debt | $84.2M | $123.0M | $159.6M | $66.4M |
SEC XBRL, fiscal years, as known on 2026-10-27
UTI Stock Sonar score 6/7 axes
Find similar shapesCompareUTI ranks highest on growth (68th percentile) and financial health (56th), and lowest on insider conviction (30th), among Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
UTI filings, in plain words
Are Universal Technical Institute insiders buying or selling UTI?
In the 180 days to 2026-10-27, Universal Technical Institute insiders were net sellers, a net $128.7M: $334.7K of purchases and $129.0M of sales reported on Form 4, by 1 buyer and 5 sellers.
Read the full summary
In the 180 days to 2026-10-27, Universal Technical Institute insiders were net sellers of UTI, a net $128.7M across purchases and sales reported on Form 4 by 1 buyer and 5 sellers. Sales outweighed purchases more than tenfold by value. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
